Drug Profile
Research programme: nitric oxide scavengers - AnorMED
Latest Information Update: 04 Apr 2007
Price :
$50
*
At a glance
- Originator AnorMED
- Developer The Institute of Cancer Research; University of Alberta; University of Calgary
- Class
- Mechanism of Action Nitric oxide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammatory bowel diseases; Septic shock; Stroke
Most Recent Events
- 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
- 30 Jul 2002 AnorMED is actively seeking partnering/licensing opportunities for its nitric oxide scavengers programme
- 29 Aug 2001 Preclinical development for Cancer in United Kingdom (Unknown route)